Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is conducting a Phase 1/2 clinical study titled A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors. The study aims to assess the safety and preliminary efficacy of SAR445877, a potential anticancer drug, in adults with advanced solid tumors.
The intervention being tested is SAR445877, administered intravenously as a monotherapy or in combination with cetuximab. SAR445877 is designed to treat various types of advanced solid tumors, including non-small cell lung cancer, hepatocellular carcinoma, gastric cancer, and colorectal cancer.
The study follows a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. It includes two parts: a dose escalation phase to determine therapeutic doses and a dose expansion phase to evaluate safety and efficacy.
The study began on November 29, 2022, with recruitment currently ongoing. The last update was submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and potential market entry timelines.
This study could significantly impact Sanofi’s stock performance, as positive results may enhance investor confidence and position the company competitively in the oncology market. The ongoing development of SAR445877 may also influence the strategies of competitors in the cancer treatment sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.